This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. and Morningstar, Inc.Ĭopyright 2022 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606Īt the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Forbes Media, LLC Investor's Business Daily, Inc. Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. See Zacks' 3 Best Stocks to Play This Trend > Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early. By 2020, it's predicted to blast through the roof to $47 billion. Last year, it generated $8 billion in global revenues. Surmodics’ long-term earnings growth rate is estimated at 10%. OPKO Health’s long-term earnings growth rate is projected at 12%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Integer Holdings has an earnings growth rate of 31.2% for the next quarter and a Zacks Rank #2 (Buy). #Marjet specialist for srdx free#( OPK Quick Quote OPK - Free Report) and Surmodics ( SRDX Quick Quote SRDX - Free Report). Some better-ranked stocks in the broader medical space are Integer Holdings Corporation ( ITGR Quick Quote ITGR - Free Report), OPKO Health, Inc. Varian Medical currently has a Zacks Rank #3 (Hold). The current level is higher than the S&P 500 index’s 0.6% decline. We believe that such positive developments are likely to boost Varian Medical’s shares, which have rallied 10.1% compared with the industry’s 12.4% rise in a year’s time. Rise in cancer prevalence, increase in collaborations between pharmaceutical companies and extensive cancer research are key factors propelling growth. Varian Medical’s ARIA oncology information system is a comprehensive information and image management solution that lets clinicians oversee all aspects of oncology care for patients.Īllied Market Research opines that the global cancer therapeutics market is estimated to reach $178,863 million by 2023, registering a CAGR of 11.9%. It is encouraging to note that last month, Medical Specialist Holdings equipped seven of its centers in South Africa with Varian linear accelerators and Eclipse treatment planning system. The system lets every patient have an optimal plan tailor-made for their respective disease needs. Interestingly, the company’s Eclipse MCO (Multi-Criteria Optimization) delivered a strong performance in the last reported quarter, with more than 250 orders across all geographies. Varian Medical’s Eclipse treatment planning system is an integrated and comprehensive one, which supports a variety of treatment options including protons, electrons, external beam, low-dose-rate brachytherapy and cobalt therapy. For investors’ notice, Varian Medical's ProBeam system is the world's first commercially available pencil beam scanning system. Notably, the IMPT treatment was delivered on a Varian ProBeam gantry. The latest development is likely to fortify Varian Medical’s foothold in the cancer therapeutics industry.įollowing the announcement, shares of Varian Medical inched up 1.4% to $120.86 at close.Ĭoming back to the news, PSI started using the Eclipse system earlier in 2018. Switzerland-based PSI is also employing Varian's ARIA oncology information management software. recently announced that Paul Scherrer Institute ("PSI") Center for Proton Therapy has begun utilizing the company’s flagship Eclipse treatment planning system for intensity modulated proton therapy (IMPT) treatments.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |